Reply to the letter to the editor: 'AJCC 8th edition staging system for pancreatic ductal adenocarcinoma: A controversial step forward?'.

Reply to the letter to the editor: 'AJCC 8th edition staging system for pancreatic ductal adenocarcinoma: A controversial step forward? Although only a few patients had pT4 disease, there was a significant difference in the survival time (16.9 months for patients with stage IIIA disease vs. 11.2 months for patients with stage IIIB disease; p < 0.01). Another study that analyzed 68 patients with pT4 disease and 41 patients with pN2 disease also showed significant differences (14.2 months for N2 patients and 12.0 months for T4 patients; p = 0.034) [[4]]. [Extracted from the article]